In this issue:
Nemolizumab for moderate-to-severe prurigo nodularis
Dupilumab for paediatric atopic dermatitis
Guselkumab for palmoplantar pustulosis
Biologic therapy and cardiometabolic risk in psoriasis
Safety events in dermatological and non-dermatological spesolimab trials
Tildrakizumab for palmoplantar plaque psoriasis
Factors impacting satisfaction in psoriatic patients receiving biological therapies
Upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis
Adalimumab for hidradenitis suppurativa
Real-world effectiveness of risankizumab in moderate-to-severe psoriasis
Please login below to download this issue (PDF)